The EU Commission sends statements of objection for alleged pay-for-delay agreement (Teva / Cephalon)

L'Ecluse, Peter

Previous article The EU Commission sends a statement of objection to a pharmaceutical company regarding a possible pay-for-delay agreement (Teva / Cephalon) Next article The UK Competition Authority alleges that two pharmaceutical companies have concluded a pay-for-delay agreement (Actavis / Concordia)

17 Jul 2017

The EU Commission sends statements of objection for alleged pay-for-delay agreement (Teva / Cephalon)

KEYWORDS

Reference

EU Commission, Teva / Cephalon, Case AT. 39686, 17 July 2017

On 17 July 2017, the European Commission issued a Statement of Objections against pharmaceutical companies Teva and Cephalon (which is now a subsidiary of Teva) alleging that Teva breached Article 101 TFEU by concluding an agreement with Cephalon not to market a cheaper generic

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Author

Peter L’Ecluse
Van Bael & Bellis (Brussels)

Belgium 141 contributions 49095 visits

Quotation

Peter L'Ecluse, The EU Commission sends statements of objection for alleged pay-for-delay agreement (Teva / Cephalon), 17 July 2017, e-Competitions Pay-for-delay agreements, Art. N° 84750

Visites 382